Evidence map›Paper›PMID 33581232›Full record

ArticleUrology2021

Real-world Compliance With Percutaneous Tibial Nerve Stimulation Maintenance Therapy in an American Population.

Chris Du, William Berg, Alexandra R Siegal, Zhenyue Huang, Rosen Jeong, Kuemin Hwang, Jason Kim

Abstract read
PubMed Publisher
In one paragraph

Article in Urology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. A First-In-Human Feasibility Study of a New Implantable Tibial Nerve Stimulator for Overactive Bladder Syndrome.Neuromodulation : journal of the International Neuromodulation Society · 2025
    Trial
  2. Article
  3. Technique for Implantable Tibial Nerve Stimulator Placement.International urogynecology journal · 2026
    Article
  4. Article
  5. Article
  6. Observational
  7. Review
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Chris DuStony Brook Medicine, Department of Urology. Electronic address: Chris.du@stonybrookmedicine.edu.
William BergStony Brook Medicine, Department of Urology.
Alexandra R SiegalMount Sinai Hospital, Department of Urology.
Zhenyue HuangStony Brook Medicine, Department of Urology.
Rosen JeongStony Brook University, Renaissance School of Medicine.
Kuemin HwangStony Brook University, Renaissance School of Medicine.
Jason KimStony Brook Medicine, Department of Urology.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate percutaneous tibial nerve stimulation (PTNS) maintenance therapy dropout rates and identify factors associated with compliance in an American population.

methodsWe retrospectively queried our PTNS database for patients from 2014-2019. Demographic, relevant clinical, and visit data were collected. Maintenance therapy was patient-driven and frequency of sessions was tapered based on symptomology. Upon completion of 12 initial sessions, we assessed dropout from maintenance at 3, 6, 9, and 12 months. Multiple variables were tested for correlation with dropout in patients continuing maintenance therapy for 1 year vs those who dropped out.

resultsOne hundred and sixty-three PTNS patients were identified, of which 104 completed initial therapy and 81 proceeded with maintenance therapy. At 3, 6, 9, and 12 months, maintenance continuation rates were 77.8% (63/81), 58.0% (47/81), 45.6% (37/81), and 39.5% (32/41), respectively. Primary reasons for dropout were worsening of urinary symptoms/lack of efficacy (n = 21), time commitment (n = 9), loss of insurance (n = 5), medical comorbidities (n = 4), request for alternative OAB treatment (n = 2), and unknown (n = 8). On both univariate and multivariate analysis, perceived symptom improvement (P<.01; HR = 0.02, P< .01) was associated with continuing maintenance therapy. On only univariate analysis, neurological history (P = .02) and multiple sclerosis history (0.02) were associated with continuing therapy.

conclusionOnly 39.5% of patients continue to undergo maintenance PTNS therapy after 1 year. Future studies are required to understand and ameliorate factors for low compliance in PTNS maintenance therapy.

Indexed as

Continuity of Patient CarePatient ComplianceTranscutaneous Electric Nerve StimulationUrinary Bladder, OveractiveFemaleHumansMaleMiddle AgedNeeds AssessmentPatient DropoutsSymptom AssessmentTibial NerveTreatment OutcomeUnited States

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.